Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 10/20 | 0.40 |
| ▸ | RAB9A | P51151 | 10/20 | 0.40 |
| ▸ | POLB | P06746 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260996 | 0.85 | CYP1A2 (0.49) | ALDH1A1KMT2ANPC1RAB9APOLB | |
| SCHEMBL12377506 | 0.85 | RAB9A (0.41) | KMT2ANPC1RAB9APOLBMEN1 | |
| SCHEMBL12362398 | 0.82 | TERT (0.46) | NPC1RAB9APOLBHPGDCA12 | |
| SCHEMBL12377505 | 0.82 | RAB9A (0.58) | ALDH1A1KMT2ANPC1RAB9APOLB | |
| SCHEMBL12377500 | 0.80 | RAB9A (0.55) | ALDH1A1KMT2ANPC1RAB9APOLB | |
| SCHEMBL12377521 | 0.78 | ALDH1A1 (0.41) | ALDH1A1POLBKDM4EHPGDCA12 | |
| SCHEMBL14173255 | 0.77 | PLAU (0.45) | ALDH1A1KMT2AKDM4EHPGDMEN1 | |
| SCHEMBL7913188 | 0.73 | BACE1 (0.39) | ALDH1A1KMT2APOLBKDM4EHPGD | |
| SCHEMBL14031250 | 0.72 | NPC1 (0.71) | ALDH1A1KMT2ANPC1RAB9APOLB | |
| SCHEMBL12362399 | 0.72 | TERT (0.42) | ALDH1A1KMT2ANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989624-B2 | Aryl spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | ALDH1A1 842/4885KMT2A 2015/4885NPC1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.